Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics

Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026. On December 2, Mizuho lowered the firm’s price target on Evolus to $19 from $20, while keeping an Outperform rating on the shares. Mizuho lowered its estimates for Evolus’s products, Jeuveau and Evolysse, due to the recent decline in consumer sentiment. The firm now expects a higher probability of sustained inflationary pressure negatively impacting demand for elective injectable facial aesthetic procedures. Despite this headwind, Miz ...